Huntington's disease / edited by Thomas N. Chase, Nancy S. Wexler, André Barbeau.
- Date:
- 1979
Licence: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Credit: Huntington's disease / edited by Thomas N. Chase, Nancy S. Wexler, André Barbeau. Source: Wellcome Collection.
842/856 page 810
![810 SUBJECTINDEX GHB, see 7-Hydroxybutyrate GUa, 90 Glial cell loss, 85 Glial filaments in astrocytic processes, 124 GUosis, GAB A receptors and, 706 Globus pallidus (GP) activity of ACE in, 518, 520 activity of GAD in, 628 behavioral effects of lesions of, 141 charge patterns of neurons in, 144-145 external and internal, 501 functional fiber connections to, 501-502 inhibition of firing of cells of, system muscimol administration and, 733 lateral, activity of COMT in, 626, 627 levels of GHB in, 560 as part of basal ganglia, 137,139 pathology of HD and, 86 substance P decrease in, 495-503 striatal neurons as cause of, 500-503 Glucosamine metabolism defect as fun¬ damental metabolic error in HD, 389 Glucosamine supplementation, 452 Glucosamine synthesis, 374-375, 377 Glucosamine-6-P synthetase, 374 [i^C] Glucosamine incorporation HD fibroblast cultures and, 378 protein glycosylation by direct measure¬ ment of, 375-381 Glucose influence on PRL secretion in HD, 299-303 Glucose tolerance test (GTT) in studying PRL secretion, 299, 300 Glutamate, 90 animal models and, 571-574 circumventricular organ regions of brain and, 609-611 evidence for transmitter function of, in dorsal horn of spinal cord, 571 high-affinity uptake of, 618-619, 621 KA and, 583, 598 low-affinity uptake of, 618-619, 621 as potent neuroexcitant, 593 role of, in HD, 540, 618-619, 621-622 as systemic axon-sparing neurotoxin, 609-611 Glutamate antagonists in treatment of HD animal studies and, 571-574 need for development of, 622 L-Glutamate decarboxylase (GAD), 527 activity in caudate, 628 in frontal cortex, 529-531, 539 in globus pallidus, 628 in HD patients, 540 in hippocampus after KA and IBO in¬ jection, 660-661 in putamen, 529-531, 534, 628 in white matter versus gray matter, 530 discussion of, 727, 785 KA Lntrastriatal injections and, 570, 583 microcomplement fixation test of, 532, 533 reduction in, 85 Glutamate receptors, chronic overstimulation of, in HD, 451 Glutamic acid, molecular structure of, 655 Glutamine, 90 inhibition of protein glycosylation by, 381- 383 reductions of, in HD patients, 540 role of, in intermediary metabolism, 374, 378 toxicity to HD ceUs, 374-375, 377 to HD fibroblasts, 375, 377, 389 F-6-P Glutamine transamidase, 383, 389 Glycerolphosphoethanolamine effect on tri- tiated G AB A binding, 711, 712 Glycolipids, incorporation of increased [^'^C] glucosamine into, 375-381 Glycopeptides, incorporation of increased [I'^C] glucosamine into, 375-381 Glycoprotein(s) biosynthesis of, 372-373 on cell surface, cell attachment to substra¬ tum and,383,384 Glycoprotein metabolism in skin fibroblasts, 389 Glycosylation in glycopeptides, inhibition by glutamine of, 382 Golgi apparatus, variations in, 117 Gonadotropic-releasing factor (GnRF) in post¬ mortem brain, 295, 296 Granular and fibrillar components of nuclear- nucleolar system, 99-105 Growth hormone (GH) effects of dopaminergic drugs on, 319-332 factors affecting release of, 291, 293 FF A and, 294 hypothalamic function and, 292 levels of apomorphine and, 325-326 bromocriptine and, 323-324 domperidone administration and, 328 L-DOPA administration and, 326 dopamine administration and, 327, 328 placebo administration and, 330 sulpiride administration and, 3 29 TRH administration and, 329 secretion dopaminergic regulation of, 311-315 effects of chlorpromazine on, 313, 314 HD and, 302](https://iiif.wellcomecollection.org/image/b18021888_0843.JP2/full/800%2C/0/default.jpg)
